无创血糖仪产品介绍1《Integrity-Applications》
相关主题
- 1、下载文档前请自行甄别文档内容的完整性，平台不提供额外的编辑、内容补充、找答案等附加服务。
- 2、"仅部分预览"的文档,不可在线预览部分如存在完整性等问题,可反馈申请退款(可完整预览的文档不适用该条件!)。
- 3、如文档侵犯您的权益，请联系客服反馈,我们会尽快为您处理(人工客服工作时间：9:00-18:30)。
Your track to health!...™
(OTCQB: IGAP)
December 2013
1
Disclaimer
This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and various provisions of the U.S. Securities Act of 1933, as amended, and the U.S. Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, included in this presentation are forward-looking statements. Forward-looking statements included in this presentation address, among other things, our future product development activities, strategies and timing of seeking regulatory approval to market our current product candidate. These statements are based on certain historical trends, current conditions and expected future developments as well as other factors the Company believes are appropriate in the circumstances. In addition to statements which explicitly describe these risks and uncertainties, readers are urged to consider statements labeled with the terms “expects”, “anticipates” and other similar words and phrases to be uncertain and forward-looking. All of the forward-looking statements made in this presentation are qualified by these cautionary statements and there can be no assurance that the actual results anticipated by the Company will be realized or, even if substantially realized, that they will have the expected consequences to or effects on the Company or its business or operations. Whether actual results will conform to the Company’s expectations and predictions is subject to a number of risks and uncertainties that may cause actual results to differ materially. See the risks described in our reports filed with the Securities and Exchange Commission, including under the heading "Risk Factors" of our Annual Report on Form 10-K for the year ended December 31, 2012.
7
Importance of SMBG is Recognized!
8
Yet Significant Barriers Exist
Prick the fingertip (ouch…) Draw blood, infuse drop onto a test strip Painful; Expensive
component to effective diabetes management;
The Diabetes Control and Complications Trial
demonstrated that intensive management reduced
the risk of complications by: 76% for eye disease; 60% for nerve disease; 50% for kidney disease.
2
Integrity Applications
Company Overview;
Glucose Monitoring;
GlucoTrack®;
Market Opportunities;
Financial Highlights;
Future Achievements and Milestones.
3
1965
1971
Leabharlann Baidu
1981
1986 1987
1993
2002
2006
A strip of paper changes its color according to the patient’s glucose level
Glucometer (Bayer) becomes the first home glucose monitoring device
technologies;
Patented proprietary algorithm.
10
Survey results: T1DM & T2DM
11
GlucoTrack® Model DF-F
Main Unit (MU) Personal Ear Clip (PEC)
12
GlucoTrack Unique Approach
4
Advances in Blood Glucose Monitoring
Meter interprets more accurately the light reflected by a color on the meter into a readable number FDA, CDC and ADA discuss SMBG: key tool in diabetes treatment First continuous glucose monitoring via a device implanted under the skin is released
Three independent (non-optical) technologies
Attempts (by others) to develop non-invasive glucose monitors have mostly been based upon optical technologies, and have not been successful
Study shows that patients who conduct SMBG reduce chances for complications (76% for eye disease, 50% for kidney disease and 60% for nerve disease) Cygnus introduces GlucoWatch. Causes skin irritation, thus cannot be called “noninvasive” 5
9
Why GlucoTrack?
Removes or diminishes the two most significant
barriers in glucose monitoring:
Pain (truly non-invasive);
Cost (no disposables).
The only device uses three independent
Developer of non-invasive glucose monitor, GlucoTrack; R&D began in 2001 (Israel); Initial prototype completed in late 2003; Methodology patent received October 2005; Incorporated in Delaware in 2010; Became an SEC reporting company on November 14, 2011.
Patented combination of technologies (simultaneously): Ultrasound Electromagnetic (Conductivity) Thermal (Heat Capacity) Unique algorithms Infrequent re-calibrations (*), by simple process
Current model, DF-F: Spot measurement device
13
GlucoTrack Features & Benefits
Easy to operate; User friendly (Just clip it! ™) Clear and simple instructions Color touch screen Large digits and Audible result within a minute History graph and list of past 1000 readings Average glucose level calculated displayed Glucose average within desired points of time Calculated HbA1c level (estimated) Easy to download data to external storage device Main Unit supports up to 3 users (individually calibrated) Measurement alerts (pre-set by users)
About Integrity Applications (OTCQB: IGAP)
We are a medical device company focused on the design, development and commercialization of noninvasive glucose monitoring devices for diabetes patients.
6
HbA1c as a Function of SMBG
HbA1c as a function of SMBG measurements per day (Source: Diabetes Atlas, 2 nd edition, 2003)
ADA (June 2012): Reducing HbA1c a Little Less than 1 Point Reduces CV Risk by 45%
Industry begins to produce lower-cost home glucose meters, allowing better access to more patients
Benefits of Frequent Glucose Monitoring
Frequent glucose monitoring is an essential
(OTCQB: IGAP)
December 2013
1
Disclaimer
This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and various provisions of the U.S. Securities Act of 1933, as amended, and the U.S. Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, included in this presentation are forward-looking statements. Forward-looking statements included in this presentation address, among other things, our future product development activities, strategies and timing of seeking regulatory approval to market our current product candidate. These statements are based on certain historical trends, current conditions and expected future developments as well as other factors the Company believes are appropriate in the circumstances. In addition to statements which explicitly describe these risks and uncertainties, readers are urged to consider statements labeled with the terms “expects”, “anticipates” and other similar words and phrases to be uncertain and forward-looking. All of the forward-looking statements made in this presentation are qualified by these cautionary statements and there can be no assurance that the actual results anticipated by the Company will be realized or, even if substantially realized, that they will have the expected consequences to or effects on the Company or its business or operations. Whether actual results will conform to the Company’s expectations and predictions is subject to a number of risks and uncertainties that may cause actual results to differ materially. See the risks described in our reports filed with the Securities and Exchange Commission, including under the heading "Risk Factors" of our Annual Report on Form 10-K for the year ended December 31, 2012.
7
Importance of SMBG is Recognized!
8
Yet Significant Barriers Exist
Prick the fingertip (ouch…) Draw blood, infuse drop onto a test strip Painful; Expensive
component to effective diabetes management;
The Diabetes Control and Complications Trial
demonstrated that intensive management reduced
the risk of complications by: 76% for eye disease; 60% for nerve disease; 50% for kidney disease.
2
Integrity Applications
Company Overview;
Glucose Monitoring;
GlucoTrack®;
Market Opportunities;
Financial Highlights;
Future Achievements and Milestones.
3
1965
1971
Leabharlann Baidu
1981
1986 1987
1993
2002
2006
A strip of paper changes its color according to the patient’s glucose level
Glucometer (Bayer) becomes the first home glucose monitoring device
technologies;
Patented proprietary algorithm.
10
Survey results: T1DM & T2DM
11
GlucoTrack® Model DF-F
Main Unit (MU) Personal Ear Clip (PEC)
12
GlucoTrack Unique Approach
4
Advances in Blood Glucose Monitoring
Meter interprets more accurately the light reflected by a color on the meter into a readable number FDA, CDC and ADA discuss SMBG: key tool in diabetes treatment First continuous glucose monitoring via a device implanted under the skin is released
Three independent (non-optical) technologies
Attempts (by others) to develop non-invasive glucose monitors have mostly been based upon optical technologies, and have not been successful
Study shows that patients who conduct SMBG reduce chances for complications (76% for eye disease, 50% for kidney disease and 60% for nerve disease) Cygnus introduces GlucoWatch. Causes skin irritation, thus cannot be called “noninvasive” 5
9
Why GlucoTrack?
Removes or diminishes the two most significant
barriers in glucose monitoring:
Pain (truly non-invasive);
Cost (no disposables).
The only device uses three independent
Developer of non-invasive glucose monitor, GlucoTrack; R&D began in 2001 (Israel); Initial prototype completed in late 2003; Methodology patent received October 2005; Incorporated in Delaware in 2010; Became an SEC reporting company on November 14, 2011.
Patented combination of technologies (simultaneously): Ultrasound Electromagnetic (Conductivity) Thermal (Heat Capacity) Unique algorithms Infrequent re-calibrations (*), by simple process
Current model, DF-F: Spot measurement device
13
GlucoTrack Features & Benefits
Easy to operate; User friendly (Just clip it! ™) Clear and simple instructions Color touch screen Large digits and Audible result within a minute History graph and list of past 1000 readings Average glucose level calculated displayed Glucose average within desired points of time Calculated HbA1c level (estimated) Easy to download data to external storage device Main Unit supports up to 3 users (individually calibrated) Measurement alerts (pre-set by users)
About Integrity Applications (OTCQB: IGAP)
We are a medical device company focused on the design, development and commercialization of noninvasive glucose monitoring devices for diabetes patients.
6
HbA1c as a Function of SMBG
HbA1c as a function of SMBG measurements per day (Source: Diabetes Atlas, 2 nd edition, 2003)
ADA (June 2012): Reducing HbA1c a Little Less than 1 Point Reduces CV Risk by 45%
Industry begins to produce lower-cost home glucose meters, allowing better access to more patients
Benefits of Frequent Glucose Monitoring
Frequent glucose monitoring is an essential